PGAM
ALNY icon

Princeton Global Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Princeton Global Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$6.75K – 756
2025
Q1 		$6.75K Sell
25
-25
-50% -$6.42K ﹤0.01% 481
2024
Q4 		$11.8K Hold
50
– – ﹤0.01% 479
2024
Q3 		$13.8K Hold
50
– – ﹤0.01% 462
2024
Q2 		$12.2K Hold
50
– – ﹤0.01% 445
2024
Q1 		$7.47K Buy
+50
New +$8.34K ﹤0.01% 458

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Princeton Global Asset Management's ALNY Position: Q2 2025 in Review

Princeton Global Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 25 shares — an estimated $6.75K sold.

Princeton Global Asset Management first reported a position in ALNY in Q1 2024 and held it in 5 quarters. The position peaked at $13.8K in Q3 2024. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Princeton Global Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Princeton Global Asset Management sold 25 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $6.75K.
  • Princeton Global Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Princeton Global Asset Management's Alnylam Pharmaceuticals position peaked at $13.8K in Q3 2024.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Princeton Global Asset Management's 13F filing for Q2 2025, filed 30 Jul 2025.